In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators.  Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

Reprogramming Immunity:  How CCR5 Blockade Could Redefine Cancer Therapy

The Rx for Biotech podcast is focused on the promise of advanced therapies and the leaders across the healthcare ecosystem bringing these innovative medicines to patients in need.  The podcast features interviews with the experts who are developing advanced therapies and AI-powered health technologies including physicians, healthcare providers, patient advocates, and technology leaders. 

To learn more about Advanced Therapies, visit our Knowledge Base:  https://www.advancedtherapiesconnect.ai/knowledge-base

To find a specialist at an advanced therapy treatment center, visit our Advanced Therapy AI-powered referral tool here:  https://www.advancedtherapiesconnect.ai/

To learn more about Genoplex, please visit https://www.genoplex.ai